NOVEMBER 2023LIFE SCIENCES REVIEW6Plasmid DNA (pDNA) manufacturing has gained significant importance in various fields, including biopharmaceuticals, gene therapy, and synthetic biology. Plasmid DNA serves as a critical tool for gene expression, gene editing, and gene delivery applications. With the advent of precision medicine, there is a growing need for customized therapeutic approaches tailored to individual patients. Plasmid DNA manufacturing enables the production of personalized gene therapies and vaccines. Modern plasmid DNA manufacturing processes aim to achieve high throughput and scalability to meet the growing demand for gene therapies and other applications. Plasmid DNA is being explored as a platform for new and emerging therapeutic modalities, like RNA-guided endonucleases, gene silencing technologies, and mRNA-based therapies. Plasmid DNA serves as a fundamental tool in synthetic biology for designing and constructing genetic circuits, metabolic pathways, and other biological systems. Through the advancement of synthetic biology, the demand for custom-designed plasmids is expected to grow. Single-use technologies are gaining popularity in biopharmaceutical manufacturing, including plasmid DNA production. They offer advantages in terms of flexibility, reduced contamination risk, and faster turnaround times.This edition of Life Sciences Review brings the latest trends and developments in the development of DNA-based vaccines, which have gained significant attention, especially in light of the COVID-19 pandemic.It features thought leadership articles from Narayana Rao, Vice President of Biopharma, Asia Pacific Middle-East Africa at Avantor, who sheds light on how the successful integration of innovative clinical development with improvements in process technologies can help companies face the constantly evolving CGT landscape. It also features an article from Yvonne Ware, Associate Director, CMC at BioNTech, who discusses the importance of using a lessons-learned tool to ensure timelines are met and products are safe for patients. This edition of Life Sciences Review spotlights Puresyn, a contract plasmid DNA manufacturing company setting the standard with its high-quality plasmid DNA by aiding in the advancements in drug research.This edition features Top Plasmid DNA Service Provider 2023; we hope you find the right partner to meet organizational needs. Let us know your thoughts!EDITORIALPlasmid DNA Manufacturing: A Key to Customized Gene TherapiesCopyright © 2023 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.Editorial StaffAaron PierceCarolynn WaltersShirley FaithRussell ThomasGilbert HooverAncel CastelinoDisclaimer: *Some of the Insights are based on our interviews with CIOs and CXOsJeremy WilliamsManaging Editoreditor@lifesciencesreview.comManaging EditorJeremy WilliamsNovember - 13 - 2023, Vol 04, Issue - 38 (ISSN 2831-8331) Published by ValleyMedia, Inc.To subscribe to Life Sciences ReviewVisit www.lifesciencesreview.com VisualizersPresley MeadowVictor Cruz Email:sales@lifesciencesreview.comeditor@lifesciencesreview.commarketing@lifesciencesreview.com
< Page 5 | Page 7 >